174 related articles for article (PubMed ID: 34282085)
1. Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review.
McCarty D; Chan B; Buchheit BM; Bougatsos C; Grusing S; Chou R
J Addict Med; 2022 May-Jun 01; 16(3):e157-e164. PubMed ID: 34282085
[TBL] [Abstract][Full Text] [Related]
2. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Pilarinos A; Bromberg DJ; Karamouzian M
JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
[TBL] [Abstract][Full Text] [Related]
3. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
[TBL] [Abstract][Full Text] [Related]
4. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
[TBL] [Abstract][Full Text] [Related]
5. Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study.
Welsh JW; Mataczynski MJ; Passetti LL; Hunter BD; Godley MD
Am J Drug Alcohol Abuse; 2022 May; 48(3):347-355. PubMed ID: 35416739
[No Abstract] [Full Text] [Related]
6. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
8. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
[TBL] [Abstract][Full Text] [Related]
9. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
10. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
11. Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.
Monico LB; Fletcher JB; Ross T; Schwartz RP; Fishman MJ; Gryczynski J; Mitchell SG
J Subst Use Addict Treat; 2024 Jul; 162():209334. PubMed ID: 38531508
[TBL] [Abstract][Full Text] [Related]
12. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Linas BP; Walley AY; LaRochelle MR
Med Care; 2022 Mar; 60(3):256-263. PubMed ID: 35026792
[TBL] [Abstract][Full Text] [Related]
13. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
14. Health care use and cost of treatment for adolescents and young adults with opioid use disorder.
Orme S; Zarkin GA; Dunlap LJ; Monico LB; Gryczynski J; Fishman MJ; Schwartz RP; O'Grady KE; Mitchell SG
J Subst Use Addict Treat; 2023 Nov; 154():209137. PubMed ID: 37558183
[TBL] [Abstract][Full Text] [Related]
15. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
17. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
McCann NC; LaRochelle MR; Morgan JR
J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
19. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.
Becker SJ; Scott K; Helseth SA; Danko KJ; Balk EM; Saldanha IJ; Adam GP; Steele DW
J Subst Abuse Treat; 2022 Jan; 132():108494. PubMed ID: 34098208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
